Table 3.
Survival outcomes of 7,001 patients with oligodendrogliomas from the SEER database, 1973–2013
| Variables | Overall | Pediatric | Adult | p-value |
|---|---|---|---|---|
| N (%) | 7,001 | 455 (6.5) | 6,546 (93.5) | – |
| Mean overall survival, years (mean ± SD) | 15.319 ± 0.324 | 30.281 ± 1.096 | 13.597 ± 0.305 | <0.001 |
| Actuarial survival by treatment, years** | ||||
| Neither | 13.860 ± 1.126 | 28.294 ± 3.021 | 11.345 ± 0.727 | <0.001 |
| Radiation only | 8.600 ± 0.492 | 9.590 ± 3.603 | 8.490 ± 0.496 | <0.001 |
| Surgery only | 20.185 ± 0.607 | 30.782 ± 1.610 | 18.179 ± 0.642 | <0.001 |
| Both | 12.427 ± 0.385 | 22.295 ± 2.121 | 11.429 ± 0.339 | <0.001 |
| Actuarial survival by primary site, years** | ||||
| Occipital lobe | 15.692 ± 1.582 | |||
| Parietal lobe | 14.376 ± 0.748 | |||
| Temporal lobe | 15.591 ± 0.652 | |||
| Frontal lobe | 14.538 ± 0.399 | |||
| Actuarial survival by size, years** | ||||
| Under 2 cm | 23.790 ± 0.709 | |||
| 2–4 cm | 24.156 ± 0.603 | |||
| Over 4 cm | 21.412 ± 0.575 | |||
| Overall mortality, N (%) | ||||
| Alive | 3,739 (53.4) | 365 (80.2) | 3,374 (51.5) | <0.001 |
| Dead | 3,262 (46.6) | 90 (19.8) | 3,172 (48.5) | <0.001 |
| Cancer-specific mortality, N (%) | ||||
| Alive | 3,739 (53.4) | 365 (80.2) | 3,374 (51.5) | <0.001 |
| Cancer death | 2,489 (35.6) | 80 (17.6) | 2,409 (36.8) | <0.001 |
| Non cancer death | 773 (11.0) | 10 (2.2) | 763 (11.7) | <0.001 |
| Cumulative survival (%) | ||||
| 1 year | 94 | 88 | <0.001 | |
| 2 years | 89 | 75 | <0.001 | |
| 5 years | 85 | 66 | <0.001 | |
Note:
**
Data presented for patients with available information only.
Abbreviations: SEER, Surveillance, Epidemiology, and End Results; N, number; SD, standard deviation.